Delivered twice a month to members, the  LTC Newsletter  provides expert analysis, updates, tips, and tools. 

Antianxiety and Hypnotic Medications

By Jane Belt, MS, RN, RAC-MT, RAC-MTA, QRP - December 02, 2020

As the COVID-19 pandemic continues, escalating case numbers, changing visitation requirements, and isolation continue to challenge nursing facilities, staff members, and residents alike. In a recent study, the Centers for Disease Control and Prevention (CDC) noted increased substance use and adverse mental health conditions during the pandemic. It remains extremely important for nursing facilities to monitor the use of all medications, particularly antianxiety and hypnotics. Some of the main groups highlighted in the study that have increased their substance usage are the general adult population, essential workers, caregivers, and the nursing home population. This article will review for nurse assessment coordinators (NACs) and other members of the interdisciplinary team (IDT) the MDS 3.0 Quality Measures (QMs) related to antianxiety and hypnotic medications.

 

Where are the MDS 3.0 Quality Measures reported?

The MDS 3.0 QM Percent of Residents Who Used an Antianxiety or Hypnotic Medication is publicly reported on Care Compare (Nursing Home Compare was retired December 1, 2020), and is a tremendous source of information for hospitals, consumers, caregivers, and residents. Facility staff need to access Care Compare and orient themselves to the information, as the data on the webpages has moved around.